Drug Recall for Palexia® SR 100mg

HPS Pharmacies wish to give notice that CSL Seqirus, in consultation with the Therapeutic Goods Administration (TGA), has initiated a drug recall for Palexia^® SR as follows:

Palexia^® SR 100mg Tablets
Tapentadol (as hydrochloride) 100 mg
ARTG 165346

The only lot affected by this recall contains the lot number: 205W01 (Expiry 02/2027)

This drug recall was initiated as the foil on the blister packaging in some packs of the affected lot is not properly secured. This may cause tablets to become loose and means the packaging is no longer child-resistant. There are no safety or efficacy concerns with the tablets. Each pack should be inspected to identify any affected blister packs from this batch.

Please inspect your stock and quarantine any defect stock. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact CSL Seqirus on 1800 008 275 or your pharmacist at HPS Pharmacies.

Download PDF